Region:Global
Product Code:GDHC157PIDR
PharmaPoint: Macular Edema-Global Drug Forecast and Market Analysis to 2026
Summary
Macular Edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as DME, a complication of diabetic retinopathy, and is the most common cause of vision loss in patients affected by diabetes mellitus. In addition the risk for ME is also higher in patients with retinal vein occlusion, a common condition in the elderly, which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).
The current standard of care for macular edema focuses around the use of anti-VEGF therapies which are administered as intravitreal injections. There are currently two approved anti-VEGF therapies on the market for the treatment of both DME and ME-RVO, Roche/Novartis' Lucentis and Regeneron/Bayer's Eylea. Roche's oncology anti-VEGF is also used off-label in many markets. Although anti-VEGF therapies represent an effective treatment for ME, many patients do not show an adequate response to such therapy. In the case of these patients, they are often moved onto second-line treatment with corticosteroids. Over the next ten years, GlobalData forecasts four novel therapies to enter the ME market: CLS-TA, Abicipar pegol, Luminate and Optina.
GlobalData estimates that drug sales for ME in 2016 were approximately $3.7 billion across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $7.0 billion at a CAGR of 6.7%. This growth will be driven by increased uptake of market leading therapy, Eylea, increased prevalence of diabetes and improved diagnosis and treatment rates. The launch of pipeline therapies will also be a driver of growth, with Allegro's Luminate and Allergan's Abicipar pegol forecast to be the highest selling pipeline agents in 2026.
Scope
Overview of macular edema, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized macular edema therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (DME, ME-BRVO and ME-CRVO) forecast from 2016 to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the macular edema therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for macular edema therapy. The most promising candidates in Phase III development are profiled.
Analysis of the current and future market competition in the global macular edema therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to-
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global macular edema therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global macular edema therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Roche/Genentech
Novartis
Regeneron
Bayer
Santen
Allergan
Alimera Sciences
Clearside BioMedical
Allegro Ophthalmics
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Significant Growth Expected in the ME Market from 2016 to 2026
2.2 Eylea Will Dominate the ME Market Through to 2025
2.3 Future Players Are Unlikely to Rival the Might of Regeneron
2.4 Despite the Availability of Anti-VEGFs, Unmet Needs Remain
2.5 Late-Stage Pipeline Therapies Will Be a Driver of Growth, Especially in the US
2.6 What Do Physicians think?
3 Introduction
3.1 Catalyst
3.2 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 DME
4.1.2 ME-RVO
4.2 Classification
4.2.1 DME
4.2.2 ME-RVO
4.3 Symptoms and Diagnosis
4.3.1 DME
4.3.2 ME-RVO
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Macular Edema (2016-2026)
5.5.1 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population
5.5.2 Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population
5.5.3 Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population
5.5.4 Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed the DME Population
5.5.5 Total Prevalent Cases of ME following BRVO
5.5.6 Age-Specific Total Prevalent Cases of ME Following BRVO
5.5.7 Sex-Specific Total Prevalent Cases of ME Following BRVO
5.5.8 Total Prevalent Cases of ME Following CRVO
5.5.9 Age-Specific Total Prevalent Cases of ME Following CRVO
5.5.10 Sex-Specific Total Prevalent Cases of ME Following CRVO
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.4 France
6.5 Germany
6.6 Italy
6.7 Spain
6.8 UK
6.9 Japan
7 Competitive Assessment
7.1 Overview
7.2 Product Profiles-Anti-VEGF Therapies
7.2.1 Lucentis (Ranibizumab)
7.2.2 Eylea (Aflibercept)
7.2.3 Avastin (Bevacizumab)
7.3 Corticosteroid Implants
7.3.1 Ozurdex (Dexamethasone Acetate)
7.3.2 Iluvien (Fluocinolone Acetonide)
8 Unmet Need and Opportunity
8.1 Overview
8.2 More Efficacious First-Line Therapies
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Longer Duration of Action
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Alternative Route of Administration
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Clinical Trial Mapping
9.3 Promising Drugs in Clinical Development
9.3.1 CLS-TA (Triamcinolone Acetonide)
9.3.2 Abicipar Pegol
9.3.3 Luminate (ALG-1001)
9.3.4 Optina (Danazol)
9.4 Promising Drugs in Early-Stage Development
9.4.1 REGN910-3 (Nesvacumab + Aflibercept)
9.4.2 RG-7716
9.4.3 AKB-9778
9.4.4 Brolucizumab (RTH258)
9.5 Other Drugs in Development
9.6 Biosimilars
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Roche/Genentech
10.3.2 Novartis
10.3.3 Regeneron
10.3.4 Bayer
10.3.5 Santen
10.3.6 Allergan
10.3.7 Alimera Sciences
10.3.8 Clearside BioMedical
10.3.9 Allegro Ophthalmics
11 Market Outlook
11.1 Global Market
11.1.1 Forecast
11.1.2 Drivers and Barriers-Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research-KOLs Interviewed for this Report
12.5 Primary Research-Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.